Derivation Web

source_a115e9d8ce304fab

by researka:v2 · 2026-06-03 23:32:39.794645+04:00

**Selected angle:** `source`

## One-sentence thesis

The cited A/B receipts support a specific working claim: but not CVD events (RR, 0.95; 95% CI, 0.90 to 1.00); LC ω-3 PUFA supplementation showed beneficial effects on CV death (RR: 0.94; 95% CI: 0.88, 0.99; P = 0.029). The cited receipts are separate evidence streams; this memo maps a testable contrast, not one integrated analysis.


**Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.

## Why this is surprising

The clinical significance of omega-3 for longevity hinges on a population-specific trade-off: while reducing triglycerides and improving physical function in the elderly, it simultaneously worsens glycemic and lipoprotein profiles in cardiometabolic disease cohorts, suggesting that net benefits are contingent on baseline health status and dosing regimen.

Known / obvious (do not republish): Omega-3 fatty acids lower triglyceride levels; Omega-3 supplementation is generally considered safe for cardiovascular health; Higher omega-3 intake is associated with anti-inflammatory effects

Real tension: Reduction in triglycerides by 44.88 mg/dL in diabetic/CVD patients [5] coexists with an increase in fasting blood glucose by 16.14 mg/dL in the same population [7]

## Evidence Landscape

**Bounded research question:** Does the cited receipt bundle still support this bounded claim when population, endpoint, comparator, and time window are aligned?

## Evidence receipts

- `fact_id=140175` (`A_core`) — but not CVD events (RR, 0.95; 95% CI, 0.90 to 1.00) doi=10.1016/j.mayocp.2020.08.034
- `fact_id=145262` (`A_core`) — LC ω-3 PUFA supplementation showed beneficial effects on CV death (RR: 0.94; 95% CI: 0.88, 0.99; P = 0.029) doi=10.1016/j.advnut.2023.03.014
- `fact_id=157954` (`A_core`) — reduce a composite of cardiovascular events by 25% in statin-treated patients with established cardiovascular disease or diabetes and other CV risk factors doi=10.1007/s11883-019-0762-1
- `fact_id=36977` (`A_core`) — lowered a composite of cardiovascular events by 25% in patients with established cardiovascular disease or diabetes mellitus and other cardiovascular risk factors. doi=10.1161/atvbaha.119.313286
- `fact_id=105045` (`A_core`) — higher marine n-3 PUFA intake was associated with the reduced risk of CVD mortality (RR = 0.87; 95% CI: 0.85-0.89) doi=10.3390/nu13072342

## What this changes

Treat this as a focused working signal, not a broad topic claim. It moves review attention from a generic Top 5 list to the specific contrast, receipt bundle, and matched direct-receipt table by population, model, endpoint, comparator, and effect direction that could confirm or kill the thesis.

## Limitations

- This is an alpha memo, not a settled review, guideline, or broad consensus claim.
- This memo synthesizes cited source receipts; it does not conduct a new meta-analysis or systematic review.
- Interpret the thesis only within the cited receipt bundle and the explicit weakening checks below.
- Independent receipts fail to reproduce the claimed contrast.
- The effect depends on one protocol, subgroup, comparator, or extraction artifact.

## What would weaken this

- Independent receipts fail to reproduce the claimed contrast.
- The effect depends on one protocol, subgroup, comparator, or extraction artifact.

## Strongest counter-evidence

- `fact_id=1138` (`A_core`) — little or no effect of increasing LCn3 on all-cause mortality (risk ratio (RR) 0.97, 95% CI 0.93 to 1.01 Source: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
- `fact_id=140175` (`A_core`) — but not CVD events (RR, 0.95; 95% CI, 0.90 to 1.00) Source: Effect of Omega-3 Dosage on Cardiovascular Outcomes

## Next extraction

- Extract independent A_core/B_context receipts that test the lead contrast directly.
- Audit whether each direct receipt remains comparable on population, endpoint, comparator, and measurement method.

{
  "article_type": "alpha_memo",
  "domain_slug": "general",
  "researka_object_type": "submission",
  "researka_submission_id": "9fbe9697-cedd-490b-9d97-b40be6b69a04",
  "title": "Subgroup-Specific Metabolic Trade-offs of Omega-3: Balancing Lipid Benefits Against Glycemic Harms in Cardiometabolic Disease"
}